Update shared on04 Aug 2025
Fair value Decreased 17%Eastman Chemical's consensus price target was revised down as analysts tempered their revenue growth outlook and reduced the expected valuation multiple, resulting in a new fair value estimate of $83.29.
What's in the News
- Repurchased 643,791 shares for $50 million, completing the buyback of 32,171,320 shares (24.84%) for $3.1 billion under its 2018 repurchase program.
- Added to multiple indices: Russell 2500 Index, Russell 2500 Value Benchmark, Russell 1000 Defensive Index, Russell 2500 Value Index, and Russell 1000 Value-Defensive Index.
- Launched Esmeri CC1N10, a biodegradable cellulose ester micropowder for color cosmetics, complying with EU microplastic regulations and offering sustainable, high-performance solutions for cosmetic formulations.
- Partnered with SUQQU to launch a recyclable luxury compact using Eastman's Cristal One copolyester, offering a sustainable alternative to ABS and aligning with evolving EU packaging regulations.
Valuation Changes
Summary of Valuation Changes for Eastman Chemical
- The Consensus Analyst Price Target has significantly fallen from $94.82 to $83.29.
- The Consensus Revenue Growth forecasts for Eastman Chemical has significantly fallen from 1.7% per annum to 1.4% per annum.
- The Future P/E for Eastman Chemical has fallen from 13.47x to 12.49x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.